nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—coronary artery disease—atherosclerosis	0.226	0.545	CtDrD
Valsartan—type 2 diabetes mellitus—atherosclerosis	0.189	0.455	CtDrD
Valsartan—AGTR1—atherosclerosis	0.189	0.809	CbGaD
Valsartan—SLCO1B3—Rosuvastatin—atherosclerosis	0.0461	0.177	CbGbCtD
Valsartan—ALB—atherosclerosis	0.0447	0.191	CbGaD
Valsartan—SLCO1B3—Pravastatin—atherosclerosis	0.0419	0.161	CbGbCtD
Valsartan—SLCO1B1—Rosuvastatin—atherosclerosis	0.0268	0.103	CbGbCtD
Valsartan—SLCO1B1—Ezetimibe—atherosclerosis	0.0268	0.103	CbGbCtD
Valsartan—SLCO1B1—Simvastatin—atherosclerosis	0.0249	0.096	CbGbCtD
Valsartan—SLCO1B1—Lovastatin—atherosclerosis	0.0244	0.0939	CbGbCtD
Valsartan—SLCO1B1—Pravastatin—atherosclerosis	0.0244	0.0939	CbGbCtD
Valsartan—ALB—Rosuvastatin—atherosclerosis	0.0147	0.0565	CbGbCtD
Valsartan—CYP2C9—Rosuvastatin—atherosclerosis	0.00792	0.0305	CbGbCtD
Valsartan—CYP2C9—Simvastatin—atherosclerosis	0.00736	0.0283	CbGbCtD
Valsartan—CYP2C9—Pravastatin—atherosclerosis	0.0072	0.0277	CbGbCtD
Valsartan—CYP2C9—Lovastatin—atherosclerosis	0.0072	0.0277	CbGbCtD
Valsartan—Forasartan—AGTR1—atherosclerosis	0.000619	0.252	CrCbGaD
Valsartan—Tasosartan—AGTR1—atherosclerosis	0.000375	0.152	CrCbGaD
Valsartan—Irbesartan—EDNRA—atherosclerosis	0.000369	0.15	CrCbGaD
Valsartan—Olmesartan—AGTR1—atherosclerosis	0.000317	0.129	CrCbGaD
Valsartan—AGTR1—artery—atherosclerosis	0.000301	0.205	CbGeAlD
Valsartan—AGTR1—endothelium—atherosclerosis	0.000254	0.173	CbGeAlD
Valsartan—Irbesartan—AGTR1—atherosclerosis	0.000247	0.1	CrCbGaD
Valsartan—Candesartan—AGTR1—atherosclerosis	0.000247	0.1	CrCbGaD
Valsartan—AGTR1—blood vessel—atherosclerosis	0.000235	0.159	CbGeAlD
Valsartan—Sinusitis—Lovastatin—atherosclerosis	0.000215	0.00403	CcSEcCtD
Valsartan—Mental disorder—Rosuvastatin—atherosclerosis	0.000213	0.00398	CcSEcCtD
Valsartan—Bronchitis—Niacin—atherosclerosis	0.000212	0.00398	CcSEcCtD
Valsartan—Sinusitis—Ezetimibe—atherosclerosis	0.000211	0.00395	CcSEcCtD
Valsartan—Flatulence—Rosuvastatin—atherosclerosis	0.000208	0.0039	CcSEcCtD
Valsartan—Hepatitis—Lovastatin—atherosclerosis	0.000206	0.00385	CcSEcCtD
Valsartan—Erectile dysfunction—Niacin—atherosclerosis	0.000203	0.00381	CcSEcCtD
Valsartan—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000202	0.00378	CcSEcCtD
Valsartan—Hepatitis—Ezetimibe—atherosclerosis	0.000202	0.00378	CcSEcCtD
Valsartan—Sinusitis—Simvastatin—atherosclerosis	0.000201	0.00377	CcSEcCtD
Valsartan—Pharyngitis—Ezetimibe—atherosclerosis	0.0002	0.00375	CcSEcCtD
Valsartan—Erectile dysfunction—Pravastatin—atherosclerosis	0.0002	0.00375	CcSEcCtD
Valsartan—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000198	0.00372	CcSEcCtD
Valsartan—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000198	0.00372	CcSEcCtD
Valsartan—Angioedema—Rosuvastatin—atherosclerosis	0.000193	0.00362	CcSEcCtD
Valsartan—Hepatitis—Simvastatin—atherosclerosis	0.000192	0.00361	CcSEcCtD
Valsartan—Cough—Rosuvastatin—atherosclerosis	0.000184	0.00346	CcSEcCtD
Valsartan—Angiopathy—Ezetimibe—atherosclerosis	0.000183	0.00343	CcSEcCtD
Valsartan—Immune system disorder—Ezetimibe—atherosclerosis	0.000182	0.00341	CcSEcCtD
Valsartan—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000182	0.00341	CcSEcCtD
Valsartan—Sinusitis—Pravastatin—atherosclerosis	0.000182	0.00341	CcSEcCtD
Valsartan—Alopecia—Lovastatin—atherosclerosis	0.000182	0.00341	CcSEcCtD
Valsartan—Arthralgia—Rosuvastatin—atherosclerosis	0.00018	0.00337	CcSEcCtD
Valsartan—Myalgia—Rosuvastatin—atherosclerosis	0.00018	0.00337	CcSEcCtD
Valsartan—Alopecia—Ezetimibe—atherosclerosis	0.000178	0.00334	CcSEcCtD
Valsartan—Haemoglobin—Niacin—atherosclerosis	0.000178	0.00333	CcSEcCtD
Valsartan—Rhinitis—Niacin—atherosclerosis	0.000177	0.00332	CcSEcCtD
Valsartan—Mental disorder—Ezetimibe—atherosclerosis	0.000177	0.00331	CcSEcCtD
Valsartan—Haemorrhage—Niacin—atherosclerosis	0.000177	0.00331	CcSEcCtD
Valsartan—Hepatitis—Niacin—atherosclerosis	0.000177	0.00331	CcSEcCtD
Valsartan—Flatulence—Lovastatin—atherosclerosis	0.000177	0.00331	CcSEcCtD
Valsartan—Malnutrition—Ezetimibe—atherosclerosis	0.000176	0.00329	CcSEcCtD
Valsartan—Dysgeusia—Lovastatin—atherosclerosis	0.000175	0.00329	CcSEcCtD
Valsartan—Rhinitis—Pravastatin—atherosclerosis	0.000174	0.00327	CcSEcCtD
Valsartan—Hepatitis—Pravastatin—atherosclerosis	0.000174	0.00326	CcSEcCtD
Valsartan—Back pain—Lovastatin—atherosclerosis	0.000173	0.00325	CcSEcCtD
Valsartan—Flatulence—Ezetimibe—atherosclerosis	0.000173	0.00324	CcSEcCtD
Valsartan—Pharyngitis—Pravastatin—atherosclerosis	0.000173	0.00324	CcSEcCtD
Valsartan—Muscle spasms—Lovastatin—atherosclerosis	0.000172	0.00323	CcSEcCtD
Valsartan—Infection—Rosuvastatin—atherosclerosis	0.000171	0.00321	CcSEcCtD
Valsartan—Alopecia—Simvastatin—atherosclerosis	0.00017	0.00319	CcSEcCtD
Valsartan—Back pain—Ezetimibe—atherosclerosis	0.00017	0.00318	CcSEcCtD
Valsartan—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000169	0.00317	CcSEcCtD
Valsartan—Muscle spasms—Ezetimibe—atherosclerosis	0.000169	0.00316	CcSEcCtD
Valsartan—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000169	0.00316	CcSEcCtD
Valsartan—Vision blurred—Lovastatin—atherosclerosis	0.000169	0.00316	CcSEcCtD
Valsartan—Mental disorder—Simvastatin—atherosclerosis	0.000169	0.00316	CcSEcCtD
Valsartan—Flatulence—Simvastatin—atherosclerosis	0.000165	0.00309	CcSEcCtD
Valsartan—Dysgeusia—Simvastatin—atherosclerosis	0.000164	0.00307	CcSEcCtD
Valsartan—Angioedema—Lovastatin—atherosclerosis	0.000164	0.00307	CcSEcCtD
Valsartan—Cardiac disorder—Pravastatin—atherosclerosis	0.000161	0.00303	CcSEcCtD
Valsartan—Muscle spasms—Simvastatin—atherosclerosis	0.000161	0.00302	CcSEcCtD
Valsartan—Vertigo—Lovastatin—atherosclerosis	0.000161	0.00301	CcSEcCtD
Valsartan—Angioedema—Ezetimibe—atherosclerosis	0.000161	0.00301	CcSEcCtD
Valsartan—Angiopathy—Niacin—atherosclerosis	0.00016	0.003	CcSEcCtD
Valsartan—Losartan—AGTR1—atherosclerosis	0.000159	0.0645	CrCbGaD
Valsartan—Vision blurred—Simvastatin—atherosclerosis	0.000158	0.00296	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000157	0.00294	CcSEcCtD
Valsartan—Alopecia—Niacin—atherosclerosis	0.000156	0.00293	CcSEcCtD
Valsartan—Insomnia—Rosuvastatin—atherosclerosis	0.000156	0.00292	CcSEcCtD
Valsartan—Palpitations—Ezetimibe—atherosclerosis	0.000155	0.00291	CcSEcCtD
Valsartan—Paraesthesia—Rosuvastatin—atherosclerosis	0.000155	0.0029	CcSEcCtD
Valsartan—Malnutrition—Niacin—atherosclerosis	0.000154	0.00288	CcSEcCtD
Valsartan—Alopecia—Pravastatin—atherosclerosis	0.000154	0.00288	CcSEcCtD
Valsartan—Cough—Ezetimibe—atherosclerosis	0.000153	0.00287	CcSEcCtD
Valsartan—Angioedema—Simvastatin—atherosclerosis	0.000153	0.00287	CcSEcCtD
Valsartan—Arthralgia—Lovastatin—atherosclerosis	0.000153	0.00286	CcSEcCtD
Valsartan—Chest pain—Lovastatin—atherosclerosis	0.000153	0.00286	CcSEcCtD
Valsartan—Myalgia—Lovastatin—atherosclerosis	0.000153	0.00286	CcSEcCtD
Valsartan—Anxiety—Lovastatin—atherosclerosis	0.000152	0.00285	CcSEcCtD
Valsartan—Dyspepsia—Rosuvastatin—atherosclerosis	0.000152	0.00284	CcSEcCtD
Valsartan—Flatulence—Niacin—atherosclerosis	0.000152	0.00284	CcSEcCtD
Valsartan—Vertigo—Simvastatin—atherosclerosis	0.000151	0.00282	CcSEcCtD
Valsartan—Chest pain—Ezetimibe—atherosclerosis	0.00015	0.0028	CcSEcCtD
Valsartan—Myalgia—Ezetimibe—atherosclerosis	0.00015	0.0028	CcSEcCtD
Valsartan—Arthralgia—Ezetimibe—atherosclerosis	0.00015	0.0028	CcSEcCtD
Valsartan—Flatulence—Pravastatin—atherosclerosis	0.000149	0.0028	CcSEcCtD
Valsartan—Dry mouth—Lovastatin—atherosclerosis	0.000149	0.00279	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000149	0.00278	CcSEcCtD
Valsartan—Dysgeusia—Pravastatin—atherosclerosis	0.000148	0.00278	CcSEcCtD
Valsartan—Muscle spasms—Niacin—atherosclerosis	0.000148	0.00277	CcSEcCtD
Valsartan—Constipation—Rosuvastatin—atherosclerosis	0.000148	0.00276	CcSEcCtD
Valsartan—Dry mouth—Ezetimibe—atherosclerosis	0.000146	0.00274	CcSEcCtD
Valsartan—Anaphylactic shock—Lovastatin—atherosclerosis	0.000146	0.00274	CcSEcCtD
Valsartan—Muscle spasms—Pravastatin—atherosclerosis	0.000146	0.00273	CcSEcCtD
Valsartan—Infection—Lovastatin—atherosclerosis	0.000145	0.00272	CcSEcCtD
Valsartan—Vision blurred—Niacin—atherosclerosis	0.000145	0.00272	CcSEcCtD
Valsartan—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000143	0.00269	CcSEcCtD
Valsartan—Thrombocytopenia—Lovastatin—atherosclerosis	0.000143	0.00268	CcSEcCtD
Valsartan—Vision blurred—Pravastatin—atherosclerosis	0.000143	0.00267	CcSEcCtD
Valsartan—Myalgia—Simvastatin—atherosclerosis	0.000143	0.00267	CcSEcCtD
Valsartan—Arthralgia—Simvastatin—atherosclerosis	0.000143	0.00267	CcSEcCtD
Valsartan—Chest pain—Simvastatin—atherosclerosis	0.000143	0.00267	CcSEcCtD
Valsartan—Infection—Ezetimibe—atherosclerosis	0.000142	0.00267	CcSEcCtD
Valsartan—Anxiety—Simvastatin—atherosclerosis	0.000142	0.00266	CcSEcCtD
Valsartan—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000141	0.00264	CcSEcCtD
Valsartan—Nervous system disorder—Ezetimibe—atherosclerosis	0.000141	0.00263	CcSEcCtD
Valsartan—Angioedema—Niacin—atherosclerosis	0.000141	0.00263	CcSEcCtD
Valsartan—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00014	0.00263	CcSEcCtD
Valsartan—Anorexia—Lovastatin—atherosclerosis	0.000139	0.00261	CcSEcCtD
Valsartan—Skin disorder—Ezetimibe—atherosclerosis	0.000139	0.00261	CcSEcCtD
Valsartan—Angioedema—Pravastatin—atherosclerosis	0.000138	0.00259	CcSEcCtD
Valsartan—Vertigo—Niacin—atherosclerosis	0.000138	0.00259	CcSEcCtD
Valsartan—Syncope—Niacin—atherosclerosis	0.000138	0.00258	CcSEcCtD
Valsartan—Urticaria—Rosuvastatin—atherosclerosis	0.000137	0.00257	CcSEcCtD
Valsartan—Oedema—Simvastatin—atherosclerosis	0.000137	0.00256	CcSEcCtD
Valsartan—Anaphylactic shock—Simvastatin—atherosclerosis	0.000137	0.00256	CcSEcCtD
Valsartan—Abdominal pain—Rosuvastatin—atherosclerosis	0.000136	0.00255	CcSEcCtD
Valsartan—Vertigo—Pravastatin—atherosclerosis	0.000136	0.00255	CcSEcCtD
Valsartan—Palpitations—Niacin—atherosclerosis	0.000136	0.00255	CcSEcCtD
Valsartan—Infection—Simvastatin—atherosclerosis	0.000136	0.00254	CcSEcCtD
Valsartan—Loss of consciousness—Niacin—atherosclerosis	0.000135	0.00253	CcSEcCtD
Valsartan—Cough—Niacin—atherosclerosis	0.000134	0.00251	CcSEcCtD
Valsartan—Thrombocytopenia—Simvastatin—atherosclerosis	0.000134	0.00251	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000133	0.00249	CcSEcCtD
Valsartan—Insomnia—Lovastatin—atherosclerosis	0.000132	0.00248	CcSEcCtD
Valsartan—Cough—Pravastatin—atherosclerosis	0.000132	0.00248	CcSEcCtD
Valsartan—Paraesthesia—Lovastatin—atherosclerosis	0.000131	0.00246	CcSEcCtD
Valsartan—Myalgia—Niacin—atherosclerosis	0.000131	0.00245	CcSEcCtD
Valsartan—Arthralgia—Niacin—atherosclerosis	0.000131	0.00245	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000131	0.00245	CcSEcCtD
Valsartan—Anorexia—Simvastatin—atherosclerosis	0.00013	0.00244	CcSEcCtD
Valsartan—Dyspnoea—Lovastatin—atherosclerosis	0.00013	0.00244	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00013	0.00244	CcSEcCtD
Valsartan—Insomnia—Ezetimibe—atherosclerosis	0.00013	0.00243	CcSEcCtD
Valsartan—Chest pain—Pravastatin—atherosclerosis	0.000129	0.00242	CcSEcCtD
Valsartan—Myalgia—Pravastatin—atherosclerosis	0.000129	0.00242	CcSEcCtD
Valsartan—Arthralgia—Pravastatin—atherosclerosis	0.000129	0.00242	CcSEcCtD
Valsartan—Paraesthesia—Ezetimibe—atherosclerosis	0.000129	0.00241	CcSEcCtD
Valsartan—Dyspepsia—Lovastatin—atherosclerosis	0.000129	0.00241	CcSEcCtD
Valsartan—Anxiety—Pravastatin—atherosclerosis	0.000129	0.00241	CcSEcCtD
Valsartan—Dry mouth—Niacin—atherosclerosis	0.000128	0.0024	CcSEcCtD
Valsartan—Dyspnoea—Ezetimibe—atherosclerosis	0.000128	0.00239	CcSEcCtD
Valsartan—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000127	0.00238	CcSEcCtD
Valsartan—Decreased appetite—Lovastatin—atherosclerosis	0.000127	0.00238	CcSEcCtD
Valsartan—Dyspepsia—Ezetimibe—atherosclerosis	0.000126	0.00236	CcSEcCtD
Valsartan—Fatigue—Lovastatin—atherosclerosis	0.000126	0.00236	CcSEcCtD
Valsartan—Oedema—Niacin—atherosclerosis	0.000126	0.00235	CcSEcCtD
Valsartan—Anaphylactic shock—Niacin—atherosclerosis	0.000126	0.00235	CcSEcCtD
Valsartan—Constipation—Lovastatin—atherosclerosis	0.000125	0.00234	CcSEcCtD
Valsartan—Decreased appetite—Ezetimibe—atherosclerosis	0.000125	0.00233	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000125	0.00233	CcSEcCtD
Valsartan—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000124	0.00232	CcSEcCtD
Valsartan—Asthenia—Rosuvastatin—atherosclerosis	0.000124	0.00232	CcSEcCtD
Valsartan—Insomnia—Simvastatin—atherosclerosis	0.000124	0.00232	CcSEcCtD
Valsartan—Oedema—Pravastatin—atherosclerosis	0.000124	0.00232	CcSEcCtD
Valsartan—Anaphylactic shock—Pravastatin—atherosclerosis	0.000124	0.00232	CcSEcCtD
Valsartan—Fatigue—Ezetimibe—atherosclerosis	0.000124	0.00232	CcSEcCtD
Valsartan—Shock—Niacin—atherosclerosis	0.000124	0.00231	CcSEcCtD
Valsartan—Infection—Pravastatin—atherosclerosis	0.000123	0.0023	CcSEcCtD
Valsartan—Paraesthesia—Simvastatin—atherosclerosis	0.000123	0.0023	CcSEcCtD
Valsartan—Constipation—Ezetimibe—atherosclerosis	0.000123	0.0023	CcSEcCtD
Valsartan—Pruritus—Rosuvastatin—atherosclerosis	0.000122	0.00229	CcSEcCtD
Valsartan—Skin disorder—Niacin—atherosclerosis	0.000122	0.00228	CcSEcCtD
Valsartan—Dyspnoea—Simvastatin—atherosclerosis	0.000122	0.00228	CcSEcCtD
Valsartan—Thrombocytopenia—Pravastatin—atherosclerosis	0.000121	0.00227	CcSEcCtD
Valsartan—Dyspepsia—Simvastatin—atherosclerosis	0.00012	0.00225	CcSEcCtD
Valsartan—AGTR1—connective tissue—atherosclerosis	0.00012	0.0817	CbGeAlD
Valsartan—Anorexia—Niacin—atherosclerosis	0.00012	0.00224	CcSEcCtD
Valsartan—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00012	0.00224	CcSEcCtD
Valsartan—Decreased appetite—Simvastatin—atherosclerosis	0.000119	0.00223	CcSEcCtD
Valsartan—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000118	0.00221	CcSEcCtD
Valsartan—Diarrhoea—Rosuvastatin—atherosclerosis	0.000118	0.00221	CcSEcCtD
Valsartan—Fatigue—Simvastatin—atherosclerosis	0.000118	0.00221	CcSEcCtD
Valsartan—Anorexia—Pravastatin—atherosclerosis	0.000118	0.00221	CcSEcCtD
Valsartan—Hypotension—Niacin—atherosclerosis	0.000117	0.0022	CcSEcCtD
Valsartan—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000117	0.0022	CcSEcCtD
Valsartan—Constipation—Simvastatin—atherosclerosis	0.000117	0.00219	CcSEcCtD
Valsartan—Urticaria—Lovastatin—atherosclerosis	0.000116	0.00218	CcSEcCtD
Valsartan—Abdominal pain—Lovastatin—atherosclerosis	0.000116	0.00216	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000114	0.00214	CcSEcCtD
Valsartan—Dizziness—Rosuvastatin—atherosclerosis	0.000114	0.00214	CcSEcCtD
Valsartan—Urticaria—Ezetimibe—atherosclerosis	0.000114	0.00213	CcSEcCtD
Valsartan—Insomnia—Niacin—atherosclerosis	0.000114	0.00213	CcSEcCtD
Valsartan—Abdominal pain—Ezetimibe—atherosclerosis	0.000113	0.00212	CcSEcCtD
Valsartan—Paraesthesia—Niacin—atherosclerosis	0.000113	0.00211	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000113	0.00211	CcSEcCtD
Valsartan—Dyspnoea—Niacin—atherosclerosis	0.000112	0.0021	CcSEcCtD
Valsartan—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000112	0.00209	CcSEcCtD
Valsartan—Insomnia—Pravastatin—atherosclerosis	0.000112	0.00209	CcSEcCtD
Valsartan—Somnolence—Niacin—atherosclerosis	0.000112	0.00209	CcSEcCtD
Valsartan—Paraesthesia—Pravastatin—atherosclerosis	0.000111	0.00208	CcSEcCtD
Valsartan—Dyspepsia—Niacin—atherosclerosis	0.000111	0.00207	CcSEcCtD
Valsartan—Dyspnoea—Pravastatin—atherosclerosis	0.00011	0.00206	CcSEcCtD
Valsartan—Decreased appetite—Niacin—atherosclerosis	0.000109	0.00204	CcSEcCtD
Valsartan—Dyspepsia—Pravastatin—atherosclerosis	0.000109	0.00204	CcSEcCtD
Valsartan—Rash—Rosuvastatin—atherosclerosis	0.000109	0.00204	CcSEcCtD
Valsartan—Dermatitis—Rosuvastatin—atherosclerosis	0.000109	0.00204	CcSEcCtD
Valsartan—Urticaria—Simvastatin—atherosclerosis	0.000109	0.00203	CcSEcCtD
Valsartan—Gastrointestinal disorder—Niacin—atherosclerosis	0.000108	0.00203	CcSEcCtD
Valsartan—Abdominal pain—Simvastatin—atherosclerosis	0.000108	0.00202	CcSEcCtD
Valsartan—Headache—Rosuvastatin—atherosclerosis	0.000108	0.00202	CcSEcCtD
Valsartan—Hypersensitivity—Lovastatin—atherosclerosis	0.000108	0.00202	CcSEcCtD
Valsartan—Decreased appetite—Pravastatin—atherosclerosis	0.000107	0.00201	CcSEcCtD
Valsartan—SLCO1B3—liver—atherosclerosis	0.000107	0.0725	CbGeAlD
Valsartan—Fatigue—Pravastatin—atherosclerosis	0.000107	0.002	CcSEcCtD
Valsartan—Constipation—Pravastatin—atherosclerosis	0.000106	0.00198	CcSEcCtD
Valsartan—Hypersensitivity—Ezetimibe—atherosclerosis	0.000106	0.00198	CcSEcCtD
Valsartan—Asthenia—Lovastatin—atherosclerosis	0.000105	0.00196	CcSEcCtD
Valsartan—AGTR1—cardiovascular system—atherosclerosis	0.000105	0.0711	CbGeAlD
Valsartan—Pruritus—Lovastatin—atherosclerosis	0.000103	0.00194	CcSEcCtD
Valsartan—Asthenia—Ezetimibe—atherosclerosis	0.000103	0.00193	CcSEcCtD
Valsartan—Gastrointestinal pain—Niacin—atherosclerosis	0.000103	0.00192	CcSEcCtD
Valsartan—Nausea—Rosuvastatin—atherosclerosis	0.000102	0.00192	CcSEcCtD
Valsartan—Pruritus—Ezetimibe—atherosclerosis	0.000101	0.0019	CcSEcCtD
Valsartan—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000101	0.00189	CcSEcCtD
Valsartan—Hypersensitivity—Simvastatin—atherosclerosis	0.000101	0.00189	CcSEcCtD
Valsartan—Diarrhoea—Lovastatin—atherosclerosis	0.0001	0.00187	CcSEcCtD
Valsartan—Urticaria—Niacin—atherosclerosis	9.97e-05	0.00187	CcSEcCtD
Valsartan—Abdominal pain—Niacin—atherosclerosis	9.93e-05	0.00186	CcSEcCtD
Valsartan—Urticaria—Pravastatin—atherosclerosis	9.82e-05	0.00184	CcSEcCtD
Valsartan—Asthenia—Simvastatin—atherosclerosis	9.81e-05	0.00184	CcSEcCtD
Valsartan—Diarrhoea—Ezetimibe—atherosclerosis	9.81e-05	0.00184	CcSEcCtD
Valsartan—Abdominal pain—Pravastatin—atherosclerosis	9.77e-05	0.00183	CcSEcCtD
Valsartan—Pruritus—Simvastatin—atherosclerosis	9.67e-05	0.00181	CcSEcCtD
Valsartan—Dizziness—Lovastatin—atherosclerosis	9.67e-05	0.00181	CcSEcCtD
Valsartan—Dizziness—Ezetimibe—atherosclerosis	9.48e-05	0.00178	CcSEcCtD
Valsartan—Diarrhoea—Simvastatin—atherosclerosis	9.36e-05	0.00175	CcSEcCtD
Valsartan—Vomiting—Lovastatin—atherosclerosis	9.3e-05	0.00174	CcSEcCtD
Valsartan—Hypersensitivity—Niacin—atherosclerosis	9.25e-05	0.00173	CcSEcCtD
Valsartan—AGTR1—adipose tissue—atherosclerosis	9.23e-05	0.0627	CbGeAlD
Valsartan—Rash—Lovastatin—atherosclerosis	9.22e-05	0.00173	CcSEcCtD
Valsartan—Dermatitis—Lovastatin—atherosclerosis	9.21e-05	0.00173	CcSEcCtD
Valsartan—Losartan—ACE—atherosclerosis	9.18e-05	0.0373	CrCbGaD
Valsartan—Headache—Lovastatin—atherosclerosis	9.16e-05	0.00172	CcSEcCtD
Valsartan—Vomiting—Ezetimibe—atherosclerosis	9.12e-05	0.00171	CcSEcCtD
Valsartan—Hypersensitivity—Pravastatin—atherosclerosis	9.11e-05	0.00171	CcSEcCtD
Valsartan—Dizziness—Simvastatin—atherosclerosis	9.04e-05	0.00169	CcSEcCtD
Valsartan—Rash—Ezetimibe—atherosclerosis	9.04e-05	0.00169	CcSEcCtD
Valsartan—Dermatitis—Ezetimibe—atherosclerosis	9.03e-05	0.00169	CcSEcCtD
Valsartan—Asthenia—Niacin—atherosclerosis	9.01e-05	0.00169	CcSEcCtD
Valsartan—Headache—Ezetimibe—atherosclerosis	8.98e-05	0.00168	CcSEcCtD
Valsartan—Pruritus—Niacin—atherosclerosis	8.88e-05	0.00166	CcSEcCtD
Valsartan—Asthenia—Pravastatin—atherosclerosis	8.87e-05	0.00166	CcSEcCtD
Valsartan—Pruritus—Pravastatin—atherosclerosis	8.75e-05	0.00164	CcSEcCtD
Valsartan—Vomiting—Simvastatin—atherosclerosis	8.69e-05	0.00163	CcSEcCtD
Valsartan—Nausea—Lovastatin—atherosclerosis	8.68e-05	0.00163	CcSEcCtD
Valsartan—Rash—Simvastatin—atherosclerosis	8.62e-05	0.00162	CcSEcCtD
Valsartan—Dermatitis—Simvastatin—atherosclerosis	8.61e-05	0.00161	CcSEcCtD
Valsartan—Diarrhoea—Niacin—atherosclerosis	8.59e-05	0.00161	CcSEcCtD
Valsartan—Headache—Simvastatin—atherosclerosis	8.57e-05	0.0016	CcSEcCtD
Valsartan—Nausea—Ezetimibe—atherosclerosis	8.52e-05	0.0016	CcSEcCtD
Valsartan—Diarrhoea—Pravastatin—atherosclerosis	8.46e-05	0.00158	CcSEcCtD
Valsartan—Dizziness—Niacin—atherosclerosis	8.3e-05	0.00156	CcSEcCtD
Valsartan—Dizziness—Pravastatin—atherosclerosis	8.18e-05	0.00153	CcSEcCtD
Valsartan—Nausea—Simvastatin—atherosclerosis	8.12e-05	0.00152	CcSEcCtD
Valsartan—Vomiting—Niacin—atherosclerosis	7.98e-05	0.0015	CcSEcCtD
Valsartan—Rash—Niacin—atherosclerosis	7.92e-05	0.00148	CcSEcCtD
Valsartan—Dermatitis—Niacin—atherosclerosis	7.91e-05	0.00148	CcSEcCtD
Valsartan—Headache—Niacin—atherosclerosis	7.87e-05	0.00147	CcSEcCtD
Valsartan—Vomiting—Pravastatin—atherosclerosis	7.86e-05	0.00147	CcSEcCtD
Valsartan—Rash—Pravastatin—atherosclerosis	7.79e-05	0.00146	CcSEcCtD
Valsartan—Dermatitis—Pravastatin—atherosclerosis	7.79e-05	0.00146	CcSEcCtD
Valsartan—Headache—Pravastatin—atherosclerosis	7.74e-05	0.00145	CcSEcCtD
Valsartan—Nausea—Niacin—atherosclerosis	7.46e-05	0.0014	CcSEcCtD
Valsartan—Nausea—Pravastatin—atherosclerosis	7.34e-05	0.00138	CcSEcCtD
Valsartan—AGTR1—liver—atherosclerosis	6.47e-05	0.044	CbGeAlD
Valsartan—SLCO1B1—liver—atherosclerosis	6.17e-05	0.0419	CbGeAlD
Valsartan—CYP2C9—cardiovascular system—atherosclerosis	5.04e-05	0.0342	CbGeAlD
Valsartan—ALB—liver—atherosclerosis	4.99e-05	0.0339	CbGeAlD
Valsartan—Losartan—ALB—atherosclerosis	3.76e-05	0.0153	CrCbGaD
Valsartan—CYP2C9—liver—atherosclerosis	3.12e-05	0.0212	CbGeAlD
Valsartan—ALB—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	1.01e-05	0.000293	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CG—atherosclerosis	1.01e-05	0.000292	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SERPINE1—atherosclerosis	9.94e-06	0.000287	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—atherosclerosis	9.88e-06	0.000285	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—APOA1—atherosclerosis	9.78e-06	0.000282	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KNG1—atherosclerosis	9.64e-06	0.000278	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KNG1—atherosclerosis	9.53e-06	0.000275	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	9.51e-06	0.000275	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	9.46e-06	0.000273	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLAUR—atherosclerosis	9.44e-06	0.000273	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL2—atherosclerosis	9.41e-06	0.000271	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	9.4e-06	0.000271	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PLAT—atherosclerosis	9.4e-06	0.000271	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	9.39e-06	0.000271	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PLG—atherosclerosis	9.34e-06	0.00027	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLG—atherosclerosis	9.23e-06	0.000266	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	9.18e-06	0.000265	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NAMPT—atherosclerosis	9.12e-06	0.000263	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	9.06e-06	0.000262	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LIPC—atherosclerosis	9.06e-06	0.000262	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	9.04e-06	0.000261	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOC3—atherosclerosis	9e-06	0.00026	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—HMOX1—atherosclerosis	9e-06	0.00026	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LDLR—atherosclerosis	8.95e-06	0.000258	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LTA4H—atherosclerosis	8.9e-06	0.000257	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCG8—atherosclerosis	8.9e-06	0.000257	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SOD1—atherosclerosis	8.85e-06	0.000255	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SOCS3—atherosclerosis	8.85e-06	0.000255	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	8.79e-06	0.000254	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CETP—atherosclerosis	8.74e-06	0.000252	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOB—atherosclerosis	8.62e-06	0.000249	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCG1—atherosclerosis	8.6e-06	0.000248	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP3—atherosclerosis	8.55e-06	0.000247	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF2—atherosclerosis	8.51e-06	0.000246	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF2—atherosclerosis	8.41e-06	0.000243	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTM1—atherosclerosis	8.38e-06	0.000242	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SCARB1—atherosclerosis	8.37e-06	0.000242	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	8.3e-06	0.00024	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOB—atherosclerosis	8.26e-06	0.000238	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—LPL—atherosclerosis	8.23e-06	0.000238	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL8—atherosclerosis	8.19e-06	0.000236	CbGpPWpGaD
Valsartan—ALB—Hemostasis—APOB—atherosclerosis	8.16e-06	0.000236	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	8.15e-06	0.000235	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EDN1—atherosclerosis	8.13e-06	0.000235	CbGpPWpGaD
Valsartan—ALB—Metabolism—FABP4—atherosclerosis	8.08e-06	0.000233	CbGpPWpGaD
Valsartan—ALB—Metabolism—LCAT—atherosclerosis	8.08e-06	0.000233	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL5—atherosclerosis	8.07e-06	0.000233	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GPX1—atherosclerosis	8.03e-06	0.000232	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PLG—atherosclerosis	7.99e-06	0.000231	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA4—atherosclerosis	7.94e-06	0.000229	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMGCR—atherosclerosis	7.91e-06	0.000228	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LPL—atherosclerosis	7.89e-06	0.000228	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CD36—atherosclerosis	7.82e-06	0.000226	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP7A1—atherosclerosis	7.8e-06	0.000225	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—atherosclerosis	7.75e-06	0.000224	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PRKCG—atherosclerosis	7.67e-06	0.000221	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PRKCG—atherosclerosis	7.58e-06	0.000219	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SPP1—atherosclerosis	7.47e-06	0.000216	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL8—atherosclerosis	7.44e-06	0.000215	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	7.43e-06	0.000214	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—MTHFR—atherosclerosis	7.41e-06	0.000214	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CD36—atherosclerosis	7.4e-06	0.000214	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	7.4e-06	0.000214	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—HMOX1—atherosclerosis	7.37e-06	0.000213	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARA—atherosclerosis	7.27e-06	0.00021	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP27A1—atherosclerosis	7.21e-06	0.000208	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	7.13e-06	0.000206	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	7.09e-06	0.000205	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—APOB—atherosclerosis	7.06e-06	0.000204	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ABCA1—atherosclerosis	7.05e-06	0.000203	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AGT—atherosclerosis	7.04e-06	0.000203	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCG1—atherosclerosis	7.04e-06	0.000203	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	6.92e-06	0.0002	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PDGFB—atherosclerosis	6.91e-06	0.000199	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOE—atherosclerosis	6.9e-06	0.000199	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—atherosclerosis	6.84e-06	0.000197	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CAV1—atherosclerosis	6.83e-06	0.000197	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA2—atherosclerosis	6.83e-06	0.000197	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLA2G2A—atherosclerosis	6.83e-06	0.000197	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALOX5AP—atherosclerosis	6.83e-06	0.000197	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALOX15—atherosclerosis	6.83e-06	0.000197	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PDGFB—atherosclerosis	6.83e-06	0.000197	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOA1—atherosclerosis	6.82e-06	0.000197	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MMP1—atherosclerosis	6.75e-06	0.000195	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCG5—atherosclerosis	6.75e-06	0.000195	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AGT—atherosclerosis	6.75e-06	0.000195	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	6.74e-06	0.000195	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LCAT—atherosclerosis	6.62e-06	0.000191	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—FABP4—atherosclerosis	6.62e-06	0.000191	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOE—atherosclerosis	6.61e-06	0.000191	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LEP—atherosclerosis	6.61e-06	0.000191	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CAV1—atherosclerosis	6.55e-06	0.000189	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOA1—atherosclerosis	6.53e-06	0.000189	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPA—atherosclerosis	6.52e-06	0.000188	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA4—atherosclerosis	6.5e-06	0.000187	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CAV1—atherosclerosis	6.47e-06	0.000187	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—MAPK3—atherosclerosis	6.47e-06	0.000187	CbGpPWpGaD
Valsartan—ALB—Hemostasis—APOA1—atherosclerosis	6.46e-06	0.000186	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP7A1—atherosclerosis	6.38e-06	0.000184	CbGpPWpGaD
Valsartan—ALB—Metabolism—BGN—atherosclerosis	6.31e-06	0.000182	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ESR1—atherosclerosis	6.31e-06	0.000182	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—atherosclerosis	6.28e-06	0.000181	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	6.27e-06	0.000181	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA5—atherosclerosis	6.25e-06	0.00018	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—F2—atherosclerosis	6.23e-06	0.00018	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CG—atherosclerosis	6.23e-06	0.00018	CbGpPWpGaD
Valsartan—ALB—Hemostasis—F2—atherosclerosis	6.16e-06	0.000178	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS2—atherosclerosis	6.09e-06	0.000176	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	6.08e-06	0.000176	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	6.07e-06	0.000175	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMOX1—atherosclerosis	6.05e-06	0.000175	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLA2G1B—atherosclerosis	6.01e-06	0.000174	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—atherosclerosis	6.01e-06	0.000173	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CG—atherosclerosis	5.97e-06	0.000172	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PPARA—atherosclerosis	5.96e-06	0.000172	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	5.95e-06	0.000172	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP27A1—atherosclerosis	5.9e-06	0.00017	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CG—atherosclerosis	5.89e-06	0.00017	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—INS—atherosclerosis	5.89e-06	0.00017	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	5.89e-06	0.00017	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	5.88e-06	0.00017	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALOX5—atherosclerosis	5.81e-06	0.000168	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	5.81e-06	0.000168	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOB—atherosclerosis	5.79e-06	0.000167	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—MAPK3—atherosclerosis	5.71e-06	0.000165	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	5.66e-06	0.000164	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—INS—atherosclerosis	5.65e-06	0.000163	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTM1—atherosclerosis	5.63e-06	0.000163	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLA2G2A—atherosclerosis	5.59e-06	0.000161	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALOX15—atherosclerosis	5.59e-06	0.000161	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALOX5AP—atherosclerosis	5.59e-06	0.000161	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA2—atherosclerosis	5.59e-06	0.000161	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—APOA1—atherosclerosis	5.59e-06	0.000161	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL2—atherosclerosis	5.56e-06	0.00016	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LPL—atherosclerosis	5.53e-06	0.00016	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCG5—atherosclerosis	5.52e-06	0.000159	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	5.52e-06	0.000159	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1—atherosclerosis	5.46e-06	0.000158	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—atherosclerosis	5.4e-06	0.000156	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF1—atherosclerosis	5.4e-06	0.000156	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPX1—atherosclerosis	5.39e-06	0.000156	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	5.37e-06	0.000155	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPA—atherosclerosis	5.33e-06	0.000154	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CD36—atherosclerosis	5.25e-06	0.000152	CbGpPWpGaD
Valsartan—ALB—Metabolism—NAMPT—atherosclerosis	5.21e-06	0.00015	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SERPINE1—atherosclerosis	5.19e-06	0.00015	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	5.18e-06	0.000149	CbGpPWpGaD
Valsartan—ALB—Metabolism—LIPC—atherosclerosis	5.18e-06	0.000149	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NOS3—atherosclerosis	5.17e-06	0.000149	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—BGN—atherosclerosis	5.17e-06	0.000149	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOC3—atherosclerosis	5.14e-06	0.000149	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	5.13e-06	0.000148	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE1—atherosclerosis	5.13e-06	0.000148	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA5—atherosclerosis	5.11e-06	0.000148	CbGpPWpGaD
Valsartan—ALB—Metabolism—LDLR—atherosclerosis	5.11e-06	0.000148	CbGpPWpGaD
Valsartan—ALB—Metabolism—CETP—atherosclerosis	4.99e-06	0.000144	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—atherosclerosis	4.98e-06	0.000144	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	4.97e-06	0.000143	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOS3—atherosclerosis	4.95e-06	0.000143	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	4.92e-06	0.000142	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS3—atherosclerosis	4.89e-06	0.000141	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARA—atherosclerosis	4.88e-06	0.000141	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	4.87e-06	0.00014	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	4.82e-06	0.000139	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	4.81e-06	0.000139	CbGpPWpGaD
Valsartan—ALB—Metabolism—SCARB1—atherosclerosis	4.78e-06	0.000138	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALOX5—atherosclerosis	4.75e-06	0.000137	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AGT—atherosclerosis	4.73e-06	0.000137	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—atherosclerosis	4.73e-06	0.000136	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOE—atherosclerosis	4.63e-06	0.000134	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAV1—atherosclerosis	4.59e-06	0.000133	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOA1—atherosclerosis	4.58e-06	0.000132	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMGCR—atherosclerosis	4.52e-06	0.00013	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—atherosclerosis	4.39e-06	0.000127	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	4.39e-06	0.000127	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—atherosclerosis	4.36e-06	0.000126	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NAMPT—atherosclerosis	4.26e-06	0.000123	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—atherosclerosis	4.24e-06	0.000122	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	4.24e-06	0.000122	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LIPC—atherosclerosis	4.24e-06	0.000122	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOC3—atherosclerosis	4.21e-06	0.000122	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LDLR—atherosclerosis	4.19e-06	0.000121	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CG—atherosclerosis	4.18e-06	0.000121	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—atherosclerosis	4.18e-06	0.000121	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CETP—atherosclerosis	4.09e-06	0.000118	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	4.07e-06	0.000118	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—atherosclerosis	4.04e-06	0.000117	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCA1—atherosclerosis	4.03e-06	0.000116	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—atherosclerosis	3.97e-06	0.000115	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—INS—atherosclerosis	3.96e-06	0.000114	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NFKB1—atherosclerosis	3.93e-06	0.000113	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SCARB1—atherosclerosis	3.91e-06	0.000113	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK8—atherosclerosis	3.86e-06	0.000112	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—atherosclerosis	3.85e-06	0.000111	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	3.81e-06	0.00011	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMGCR—atherosclerosis	3.7e-06	0.000107	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—atherosclerosis	3.63e-06	0.000105	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—atherosclerosis	3.57e-06	0.000103	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—atherosclerosis	3.53e-06	0.000102	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—atherosclerosis	3.53e-06	0.000102	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NOS3—atherosclerosis	3.47e-06	0.0001	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMOX1—atherosclerosis	3.45e-06	9.97e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK3—atherosclerosis	3.38e-06	9.74e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	3.33e-06	9.63e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MAPK3—atherosclerosis	3.33e-06	9.63e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOB—atherosclerosis	3.31e-06	9.55e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCA1—atherosclerosis	3.3e-06	9.51e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—atherosclerosis	3.27e-06	9.45e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—atherosclerosis	3.24e-06	9.34e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTM1—atherosclerosis	3.22e-06	9.29e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—atherosclerosis	3.18e-06	9.17e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPL—atherosclerosis	3.16e-06	9.12e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX1—atherosclerosis	3.08e-06	8.9e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CD36—atherosclerosis	3e-06	8.66e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—atherosclerosis	2.84e-06	8.21e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMOX1—atherosclerosis	2.83e-06	8.16e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARA—atherosclerosis	2.79e-06	8.05e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOB—atherosclerosis	2.71e-06	7.82e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AGT—atherosclerosis	2.7e-06	7.8e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOE—atherosclerosis	2.65e-06	7.64e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM1—atherosclerosis	2.63e-06	7.6e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAV1—atherosclerosis	2.62e-06	7.57e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA1—atherosclerosis	2.62e-06	7.56e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPL—atherosclerosis	2.59e-06	7.46e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX1—atherosclerosis	2.52e-06	7.28e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—atherosclerosis	2.47e-06	7.12e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CD36—atherosclerosis	2.46e-06	7.09e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CG—atherosclerosis	2.39e-06	6.9e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—atherosclerosis	2.38e-06	6.86e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—atherosclerosis	2.33e-06	6.72e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—atherosclerosis	2.31e-06	6.66e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARA—atherosclerosis	2.28e-06	6.59e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—atherosclerosis	2.28e-06	6.57e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—INS—atherosclerosis	2.26e-06	6.53e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—atherosclerosis	2.25e-06	6.49e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AGT—atherosclerosis	2.21e-06	6.39e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOE—atherosclerosis	2.17e-06	6.26e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAV1—atherosclerosis	2.15e-06	6.2e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA1—atherosclerosis	2.14e-06	6.18e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NOS3—atherosclerosis	1.98e-06	5.73e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CG—atherosclerosis	1.96e-06	5.65e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—atherosclerosis	1.89e-06	5.45e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—INS—atherosclerosis	1.85e-06	5.34e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—atherosclerosis	1.81e-06	5.24e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—atherosclerosis	1.7e-06	4.9e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NOS3—atherosclerosis	1.62e-06	4.69e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—atherosclerosis	1.6e-06	4.61e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—atherosclerosis	1.49e-06	4.29e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—atherosclerosis	9.12e-07	2.63e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—atherosclerosis	7.46e-07	2.15e-05	CbGpPWpGaD
